Emerging data about benefits of the newer weight-loss drugs for some chronic skin conditions suggests their potential use in dermatology, as well as a role for dermatologists in obesity management. Glucagon like peptide 1 receptor agonist (GLP-1 RA) medications began as treatments for type 2 diabetes (T2D), then emerged as weight-loss drugs. The newer generation … Read more
Psoriasis, which affects approximately 7.5 million people in the United States, is a chronic, immune-mediated dermatological disorder characterized by keratinocyte hyperproliferation, often presenting as erythematous, scaly plaques on the skin. In some cases, it is accompanied by psoriatic arthritis (PsA), a seronegative oligoarthritis marked by progressive joint pain and destruction. While pharmacologic interventions, including biologic … Read more
The need to recognize and manage chronic nociplastic pain has become integral to rheumatology practice, as research over the past half-decade has affirmed that when central sensitization is present, patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (AxSpA), and other rheumatologic diseases are less responsive — or nonresponsive — to peripherally and axially … Read more
TOPLINE: According to a study of over five million patients with a neoplasm, those who received an immune checkpoint inhibitor (ICI) faced a 26% higher risk for rheumatoid arthritis (RA) than those receiving other types of cancer therapy. METHODOLOGY: Researchers conducted this retrospective observational study using data from the global federated research network TriNetX to … Read more